3759 — Pharmaron Beijing Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapFalling Star

Annual income statement for Pharmaron Beijing Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,444	10,266	11,538	12,276	14,095
Cost of Revenue
Gross Profit	2,676	3,764	4,116	4,184	4,890
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,529	8,576	9,690	10,171	12,167
Operating Profit	1,914	1,690	1,848	2,104	1,928
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	1,911	1,666	1,838	2,091	1,913
Provision for Income Taxes
Net Income After Taxes	1,620	1,352	1,582	1,714	1,555
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,661	1,375	1,601	1,793	1,664
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,661	1,375	1,601	1,793	1,664
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.913	0.662	0.88	1.06	0.943
Dividends per Share